The interaction between growth hormone pathway activation and triple-receptor incretin agonism has zero clinical data supporting its safety or efficacy
Some of the more common side effects in clinical trials compared to placebo include: Gastrointestinal side effects such as nausea, vomiting, constipation, or diarrhea Abdominal pain Headache, dizziness Fatigue Dyspepsia, abdominal distension, eructation Hypoglycemia (low blood sugar) in patients with type 2 diabetes Flatulence, gastroenteritis, and gastroesophageal reflux disease (heartburn) Hypoglycemia (low blood sugar levels), a more serious side effect of GLP-1 drugs, may also occur
Body image improvements tend to maintain their positive effect on desire as long as the weight remains stable
Clinicians and patients should not assume the full safety profile yet unless the medication receives FDA approval
[DOI] [PubMed] [Google Scholar] 83.Vilsbll T, et al